| Product vision |
- Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
- Potential for use in severe malaria
|
| MoA |
- Inhibition of acetylCoA synthetase (acetylCS)
- No pre-existing resistance, no resistance in vitro
|
| Key features |
- Novel mechanism of action
- Blood stage P. falciparum infection & blocks transmission
- Predicted human efficacious dose = 100 mg single dose
- High solubility and good overall physical properties
|
| Challenges |
- Safety (absence of mechanism-based toxicity)
|
| Status |
|
| Next milestone |
- GLP toxicology and safety pharmacology
- Optimization of synthesis route, CMC and formulation
|
| Previously |
- From a discovery collaboration with TropIQ
|
| MMV Project Director |
|
